Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Organogenesis Holdings's retained earnings for the quarter that ended in Mar. 2026 was $-56.2 Mil.
Organogenesis Holdings's quarterly retained earnings
increased
from Sep. 2025 ($-46.8 Mil) to Dec. 2025 ($-3.1 Mil) but then
declined
from Dec. 2025 ($-3.1 Mil) to Mar. 2026 ($-56.2 Mil).
Organogenesis Holdings's annual retained earnings
increased
from Dec. 2023 ($-41.0 Mil) to Dec. 2024 ($-40.1 Mil) and
increased
from Dec. 2024 ($-40.1 Mil) to Dec. 2025 ($-3.1 Mil).
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Organogenesis Holdings Retained Earnings Historical Data
* Premium members only.
The historical data trend for Organogenesis Holdings's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Organogenesis Holdings (ORGO) has a Retained Earnings of $-56.2 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Organogenesis Holdings and its competitors.
Is Organogenesis Holdings' Retained Earnings too high?
Organogenesis Holdings' current Retained Earnings is $-56.2 Mil. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Retained Earnings compare to TKNO and AKBA?
Organogenesis Holdings' Retained Earnings of $-56.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Organogenesis Holdings and its competitors. Organogenesis Holdings's current Retained Earnings is $-56.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (ORGO) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.05, compared to a current price of $2.40 — trading 21.5% below its estimated fair value. The current Retained Earnings is $-56.2 Mil. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Organogenesis Holdings (ORGO), the current Retained Earnings is $-56.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organogenesis Holdings (ORGO) Overvalued in 2026?
Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued.
The current stock price of $2.40 is trading 21.5% below its estimated GF Value™ of $3.05.
GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.
Key valuation signals for ORGO:
Retained Earnings: $-56.2 Mil
GF Value™: $3.05 vs. price of $2.40 (21.5% below fair value)
No single metric tells the full story. See the ORGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score
Get the complete analysis for ORGO
Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORGO has been successfully added to your 
